But beneath the selloff, something unusual has emerged. Novo Nordisk is no longer priced like a hypergrowth AI-era healthcare leader. It's priced like a slow-growth legacy pharma stock. At just 10.6x ...
Source LinkBut beneath the selloff, something unusual has emerged. Novo Nordisk is no longer priced like a hypergrowth AI-era healthcare leader. It's priced like a slow-growth legacy pharma stock. At just 10.6x ...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.